X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Natco Pharma Fact Sheet, Natco Pharma Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Natco Pharma Fact Sheet   (NTPH)

Here is the latest financial fact sheet of Natco Pharma. For more details, see the Natco Pharma quarterly results and Natco Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

NATCO PHARMA Price History

Price Rs 1,012.7
Mkt Cap Rs m 168,252
Vol '000 1.8
P/E X 30.6
P/CF X 130.9
EPS (TTM) Rs 33.1
% ch % 0.7
No. of shares m 166.15
% ch week % -0.9
% ch 1-mth % 0.5
% ch 12-mth % 57.2
52 week H/L Rs 1,080.0/581.3
(As on Jan 19, 2018 11:17:00 AM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

NATCO PHARMA Financials

No. of Mths
Year Ending
12
Mar-10
*
12
Mar-11
*
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
5-Yr Chart
Click to enlarge
NATCO PHARMA EQUITY SHARE DATA
High Rs156358361505877 
Low Rs47134197330424 
Sales per share (Unadj.) Rs162.2163.3168.1210.6223.4 
Earnings per share (Unadj.) Rs17.319.019.122.931.1 
Diluted earnings per shareRs2.93.23.64.36.2 
Cash flow per share (Unadj.) Rs24.324.724.230.040.3 
Dividends per share (Unadj.) Rs2.002.003.004.005.00 
Adj. dividends per shareRs0.340.340.560.761.00 
Dividend yield (eoy) %2.00.81.11.00.8 
Book value per share (Unadj.) Rs108.6125.2152.0170.1219.5 
Adj. book value per shareRs18.421.228.532.143.7 
Shares outstanding (eoy) m28.1528.1531.1531.3733.07 
Bonus/Rights/Conversions  ESOP-PPESOPPA 
Price / Sales ratio x0.61.51.72.02.9 
Avg P/E ratio x5.912.914.618.220.9 
P/CF ratio (eoy) x4.210.011.513.916.1 
Price / Book Value ratio x0.92.01.82.53.0 
Dividend payout %11.610.515.717.516.1 
Avg Mkt Cap Rs m2,8576,9258,69113,10021,504 
No. of employees `000NANANANANA 
Total wages/salary Rs m5896648011,0231,128 
Avg. sales/employee Rs ThNMNMNMNMNM 
Avg. wages/employee Rs ThNMNMNMNMNM 
Avg. net profit/employee Rs ThNMNMNMNMNM 
NATCO PHARMA INCOME DATA
Net Sales Rs m4,5674,5975,2376,6057,389 
Other income Rs m464691124167 
Total revenues Rs m4,6134,6435,3296,7297,556 
Gross profit Rs m9138891,0941,4991,793 
Depreciation Rs m197159159221304 
Interest Rs m130125230263366 
Profit before tax Rs m6326517951,1391,290 
Minority Interest Rs m816116046 
Prior Period Items Rs m-160000 
Extraordinary Inc (Exp) Rs m000-1160 
Tax Rs m137132211364309 
Profit after tax Rs m4875355967191,027 
Gross profit margin %20.019.320.922.724.3 
Effective tax rate %21.620.326.532.023.9 
Net profit margin %10.711.611.410.913.9 
NATCO PHARMA BALANCE SHEET DATA
Current assets Rs m1,9232,4702,9283,3053,681 
Current liabilities Rs m1,6461,9342,5943,4493,123 
Net working cap to sales %6.111.76.4-2.27.6 
Current ratio x1.21.31.11.01.2 
Inventory Days Days6281778189 
Debtors Days Days4656667259 
Net fixed assets Rs m3,0143,4614,8406,8867,685 
Share capital Rs m282282312314331 
"Free" reserves Rs m2,5363,0054,1384,7686,670 
Net worth Rs m3,0573,5244,7365,3357,259 
Long term debt Rs m5221,2541,3411,378955 
Total assets Rs m5,5437,0739,05210,80411,957 
Interest coverage x5.86.24.55.34.5 
Debt to equity ratio x0.20.40.30.30.1 
Sales to assets ratio x0.80.60.60.60.6 
Return on assets %11.19.39.19.111.7 
Return on equity %15.915.212.613.514.2 
Return on capital %21.116.617.120.120.7 
Exports to sales %21.128.334.242.739.4 
Imports to sales %4.17.07.47.45.7 
Exports (fob) Rs m9641,3011,7902,8172,908 
Imports (cif) Rs m187323388486421 
Fx inflow Rs m9821,3992,1783,2053,445 
Fx outflow Rs m209446570628703 
Net fx Rs m7749531,6082,5772,743 
NATCO PHARMA CASH FLOW
From Operations Rs m 774 370 649 612 1,440 
From Investments Rs m -609 -888 -1,269 -1,071 -1,089 
From Financial Activity Rs m -342 771 628 263 -353 
Net Cashflow Rs m -176 253 8 -196 -1 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 52.0%
Foreign collaborators 1.5%
Indian inst/Mut Fund 7.8%
FIIs 16.6%
ADR/GDR 0.0%
Free float 26.0%
Shareholders 25,395
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF NATCO House, Road No.2, Banjara Hills, Hyderabad - 500 033
E-MAIL investors@natcopharma.co.in WEB www.natcopharma.co.in
TELEPHONE (040) 2354 7532 FAX (040) 2354 8243
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Venture Capital, 12-10-167, Bharatnagar, Hyderabad-500 018
AUDITOR Walker, Chandiok & Co.
CHM: V. C. Nannapaneni (MD) COMP SEC: M. Adinarayana YEAR OF INC: 1981 BSE CODE: 524816 FV (Rs): 10 DIV YIELD (%): 0.1

More Pharmaceuticals Company Fact Sheets:   ORCHID PHARMA LTD  J.B.CHEMICALS  DR. REDDYS LAB  SUVEN LIFE  PANACEA BIOTECH  

Compare NATCO PHARMA With:   ORCHID PHARMA LTD  J.B.CHEMICALS  DR. REDDYS LAB  SUVEN LIFE  PANACEA BIOTECH  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Share Markets Open Flat; Yes Bank Top Gainer(09:30 am)

Asian stock markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.31% while the Hang Seng is up 0.07%. The Shanghai Composite is trading up by 0.35%.

Views on news

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON NATCO PHARMA

NATCO PHARMA - ACTAVIS COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS